Skip to content

Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

Comparison of Clinical Efficacy of Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04990336
Enrollment
306
Registered
2021-08-04
Start date
2023-09-01
Completion date
2029-07-31
Last updated
2022-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Keywords

Acute Pancreatitis, Dachaihu Decoction Compound, Rhubarb Single Medicine

Brief summary

A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.

Interventions

COMBINATION_PRODUCTDachaihu decoction compound

Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.

DRUGRhubarb single medicine

Rhubarb single medicine

COMBINATION_PRODUCTRegular therapies

Regular therapies, such as fluid therapy, for acute pancreatitis

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 65 years old * Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset * Consent of the subjects, who sign the informed consent form

Exclusion criteria

* Women who are pregnant or breastfeeding * Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc. * Patients with a history of severe heart, liver, kidney and other important organ diseases * Patients with mental illness and malignant tumors * People who have allergies, or are allergic to a certain drug ingredient

Design outcomes

Primary

MeasureTime frameDescription
Significant and effective rate7 daysSignificant and effective rate after 7 days of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026